Hypofractionated intensity-modulated radiation therapy with concurrent chemotherapy in muscle-invasive bladder cancer: A prospective phase II exploratory trial (HIRACOM)

Samsung Medical Center0 个研究点目标入组 53 人开始时间: 待定最近更新: 2021年4月22日

试验速览

暂无简介。

•1) Patients diagnosed with bladder cancer histologically
•2) Patients with muscle layer involvement in transurethral resection (pT2 or higher)
•3) Patients without pelvic lymph node metastasis by computed tomography (CT) or magnetic resonance images (MRI) of the pelvis.
•4) Patients who want bladder conservation treatment
•5) Patients over 20 years old
•6) Patients with Zubrod (ECOG) performance status 0-1 within 1 week prior to participation in the study
•7) Patients who have signed the consent form with sufficient information by the patient or guardian
•8) Patients with hematologic findings capable of concurrent chemoradiotherapy

•1) Patients with previous pelvic radiotherapy history
•2) Pregnant or lactating patients
•3) Patients with distant metastasis
•4) Patients judged to be difficult to conserve bladder due to extensive non-invasive/invasive bladder cancer
•5) Patients who have not been disease-free for more than 5 years after diagnosis of cancer (excluding thyroid cancer, non-melanoma skin cancer, T1a prostate cancer, and intraepithelial cancer of the cervix)
•6) Patients with untreated severe acute disease
•7) Patients predicted to have a high probability of radiation complications due to connective tissue disease (lupus, scleroderma, etc.)

发起方